Drug Trial Radar · NCT07276997
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
195
Planned (sponsor's estimate)
Start
Dec 18, 2025
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains. This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE). Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with major depressive disorder. Participants are placed in 1 of 3 groups, called treatment arms. There is a 1 in 3 chance that a participant will be assigned to placebo treatment. Around 195 adult participant with major depressive disorder will be enrolled in approximately 35 sites in North America. Participants will receive oral capsules of Icalcaprant or matching placebo once daily for 6 weeks, with a 30-day safety follow-up. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Major Depressive Disorder
Interventions
IcalcaprantDrug
Oral Capsules
Placebo for IcalcaprantDrug
Oral Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score.Time frame: Up to approximately 6 weeks
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 10 weeks
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
Harmonex /ID# 277517
Dothan, Alabama · Recruiting
Ima Clinical Research Phoenix (Alea) /ID# 277516
Phoenix, Arizona · Recruiting
Preferred Research Partners /ID# 279206
Little Rock, Arkansas · Recruiting
Woodland International Research Group /ID# 277605
Little Rock, Arkansas · Recruiting
Advanced Research Center /ID# 277537
Anaheim, California · Recruiting
Sun Valley Research Center /ID# 277513
Imperial, California · Recruiting
Synergy San Diego /ID# 277553
Lemon Grove, California · Recruiting
Accellacare - Long Beach /ID# 279181
Long Beach, California · Recruiting
CenExel CNR /ID# 277533
Sherman Oaks, California · Recruiting
Inland Psychiatric Medical Group /ID# 279275
Temecula, California · Recruiting
Sunwise Clinical Research /ID# 277555
Walnut Creek, California · Recruiting
CenExel Hollywood FL /ID# 278200
Hollywood, Florida · Recruiting
Cns Healthcare - Jacksonville /ID# 277658
Jacksonville, Florida · Recruiting
GMI Florida - Central Miami Medical Institute /ID# 278218
Miami, Florida · Recruiting
Clinical Neuroscience Solutions - Orlando - East South Street /ID# 277558
Orlando, Florida · Recruiting
EquiPath Health & Research Tampa Bay, LLC /ID# 279128
Riverview, Florida · Recruiting
Trialmed /ID# 277601
Atlanta, Georgia · Recruiting
Evergreen Clinical Trials - Norcross /ID# 279421
Norcross, Georgia · Recruiting
Flourish Research - Great Lakes Clinical Trials /ID# 278201
Chicago, Illinois · Recruiting
Amr Conventions Research /ID# 277547
Warrenville, Illinois · Recruiting
Redbird Research /ID# 277485
Las Vegas, Nevada · Recruiting
Ima Clinical Research - Manhattan /ID# 278212
New York, New York · Recruiting
Manhattan Behavioral Medicine /ID# 277910
New York, New York · Recruiting
Quest Therapeutics of Avon /ID# 277550
Avon Lake, Ohio · Recruiting
OSU Psychiatry Department /ID# 277529
Columbus, Ohio · Recruiting
Sooner Clinical Research /ID# 277659
Oklahoma City, Oklahoma · Recruiting
Clinical Neuroscience Solutions /ID# 278192
Memphis, Tennessee · Recruiting
Austin Clinical Trial Partners /ID# 279321
Austin, Texas · Recruiting
Community Clinical Research - Cross Park Drive /ID# 277935
Austin, Texas · Recruiting
Houston Clinical Trials - Bellaire /ID# 277551
Bellaire, Texas · Recruiting
Pillar Clinical Research - Richardson /ID# 276764
Richardson, Texas · Recruiting
Northwest Clinical Research Center /ID# 277484
Bellevue, Washington · Recruiting
Core Clinical Research /ID# 277518
Everett, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.